<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079417</url>
  </required_header>
  <id_info>
    <org_study_id>ARET0331</org_study_id>
    <secondary_id>NCI-2009-00422</secondary_id>
    <secondary_id>CDR0000355721</secondary_id>
    <secondary_id>COG-ARET0331</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT00079417</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma</brief_title>
  <official_title>Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial is studying how well giving carboplatin and vincristine together with
      standard local ophthalmic therapy works in treating children with intraocular retinoblastoma.
      Drugs used in chemotherapy, such as carboplatin and vincristine, work in different ways to
      stop tumor tumor from dividing so they stop growing or die. It is not yet known whether
      neoadjuvant chemotherapy combined with standard local ophthalmic therapy is effective in
      treating intraocular retinoblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the 2-year event-free survival of patients with Group B intraocular
      retinoblastoma treated with neoadjuvant chemoreduction comprising carboplatin and vincristine
      and standardized local ophthalmic therapy.

      SECONDARY OBJECTIVES:

      I. Determine the response rate after one course of chemoreduction (before standardized local
      ophthalmic therapy) in these patients.

      II. Correlate response rate with event-free survival in patients treated with this regimen.

      III. Determine the incidence of toxic effects in patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      Patients receive chemoreduction comprising carboplatin IV over 60 minutes followed by
      vincristine IV over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in
      the absence of disease progression or unacceptable toxicity. After the first course of
      chemoreduction, patients undergo standardized local ophthalmic therapy comprising local laser
      therapy, cryotherapy, and/or radioactive plaque comprising iodine I 125 or ruthenium Ru 106.

      Patients are followed every 3-4 weeks until there is no active tumor seen on a minimum of 3
      ophthalmic exams under anesthesia, every 6-8 weeks until 3 years of age, every 4-6 months
      until 10 years of age, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date>January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>At 2 years</time_frame>
    <description>Proportion of patients with event free survival at 2 years. An event is defined as the need for non-protocol therapy, defined as additional on-protocol chemotherapy, enucleation or external beam radiation, among patients with Group B intraocular tumors with a schedule of neoadjuvant 2-agent (Vincristine/Carboplatin) chemotherapy (chemo-reduction) and standardized local ophthalmic therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of Nonprotocol Chemotherapy</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Use of nonprotocol chemotherapy at the patient level and enucleation and EBRT will be descriptively summarized at the patient and eye levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR) at Patient and Eye Levels After the First Course</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>RR will be estimated. The response after 1 course of chemotherapy will be used to better define response to this neoadjuvant systemic chemotherapy, prior to the use of local ophthalmic therapy. Response to subsequent courses will help define response to combined systemic chemotherapy and local ophthalmic therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival Rate (EFSR) Defined as the Need for Non-protocol Chemotherapy, Enucleation, or EBRT at the Patient Level</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>EFSR will be estimated for patients who respond to vincristine and carboplatin after an initial 1 cycle of chemoreduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0</measure>
    <time_frame>From the beginning of treatment, assessed up to 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Intraocular Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>Vincristine Sulfate and Carboplatin and surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive chemoreduction comprising carboplatin IV (Pts &lt; 36 months: 18.6 mg/kg Pts ≥ 36 months: 560 mg/m2) over 60 minutes followed by vincristine sulfate IV (Pts &lt; 36 months: 0.05 mg/kg Pts ≥36 months: 1.5 mg/m2) over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local infrared laser therapy, cryosurgery, and/or radiation therapy (radioactive) plaque comprising iodine I 125 or ruthenium Ru 106.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cryosurgery</intervention_name>
    <description>Application of extreme cold to destroy abnormal or diseased tissue.</description>
    <arm_group_label>Vincristine Sulfate and Carboplatin and surgery</arm_group_label>
    <other_name>cryoablation</other_name>
    <other_name>cryosurgical ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>infrared laser therapy</intervention_name>
    <description>Laser therapy or &quot;photobiomodulation&quot; is the use of specific wavelength of light (red and near-infrared) to create therapeutic effects</description>
    <arm_group_label>Vincristine Sulfate and Carboplatin and surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 125</intervention_name>
    <description>Undergo radioactive therapy</description>
    <arm_group_label>Vincristine Sulfate and Carboplatin and surgery</arm_group_label>
    <other_name>125-Iodine</other_name>
    <other_name>I-125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>ruthenium Ru 106</intervention_name>
    <description>Undergo radioactive therapy</description>
    <arm_group_label>Vincristine Sulfate and Carboplatin and surgery</arm_group_label>
    <other_name>Ru-106</other_name>
    <other_name>Ruthenium 106</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Vincristine Sulfate and Carboplatin and surgery</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Vincristine Sulfate and Carboplatin and surgery</arm_group_label>
    <other_name>leurocristine sulfate</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincasar PFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radioactive therapy</description>
    <arm_group_label>Vincristine Sulfate and Carboplatin and surgery</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed Group B intraocular retinoblastoma meeting 1 of the following
             criteria:

               -  Group B tumor(s) in 1 eye

               -  Group B tumor(s) in both eyes

               -  Group A tumor in 1 eye and Group B tumor(s) in the other eye

               -  Group E tumor in 1 eye that has been enucleated and Group B tumor(s) in the
                  remaining eye at the time of enucleation of the Group E tumor

          -  Defined by the International Classification System for Intraocular Retinoblastoma as
             follows:

               -  Group A: Small tumors (≤ 3 mm in greatest dimension) confined to the retina, away
                  from foveola and disc meeting the following criteria:

                    -  More than 3 mm from fovea

                    -  More than 1.5 mm from optic disk

               -  Group B: Tumors more than 3 mm meeting the following criteria:

                    -  Confined to the retina in any location not in Group A

                    -  Tumor associated subretinal fluid &lt; 3 mm from the tumor margin with no
                       subretinal seeding

               -  Group E: Must have ≥ 1 of the following present:

                    -  Tumor touching the lens

                    -  Tumor anterior to anterior vitreous face involving ciliary body or anterior
                       segment

                    -  Diffuse infiltrating retinoblastoma

                    -  Neovascular glaucoma

                    -  Opaque media from hemorrhage

                    -  Tumor necrosis with aseptic orbital cellulites

                    -  Phthisis bulbi

          -  Confirmation of diagnosis by CT scan or MRI of the brain and orbits AND an
             ophthalmologic evaluation under anesthesia within the past 3 weeks

          -  No choroidal and/or optic nerve invasion past the lamina cribosa

          -  No evidence of extraocular retinoblastoma clinically or by head and orbital MRI and/or
             CT scan

          -  No tumor present on histological exam at the cut end of the optic nerve for any Group
             E eye enucleated before study entry

          -  Performance status - ECOG 0-2

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age

          -  AST or ALT &lt; 2.5 times ULN for age

          -  Creatinine clearance (based on Schwartz formula) or radioisotope glomerular filtration
             rate ≥ 70mL/min/1.73 m^2

          -  No prior chemotherapy

          -  No other concurrent chemotherapy

          -  No prior radiotherapy

          -  No other concurrent radiotherapy, including intensity-modulated stereotactic, or
             proton beam radiotherapy

          -  Prior enucleation of one eye allowed provided the remaining eye is Group B

          -  No concurrent enucleation

          -  No prior local ophthalmic therapy for retinoblastoma

          -  No other prior therapy for retinoblastoma

          -  No local therapy during chemotherapy course 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Monrovia</city>
        <state>California</state>
        <zip>91016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2004</study_first_posted>
  <results_first_submitted>December 23, 2013</results_first_submitted>
  <results_first_submitted_qc>December 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 14, 2014</results_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Iodine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vincristine Sulfate and Carboplatin and Surgery</title>
          <description>Patients receive chemoreduction comprising carboplatin IV (Pts &lt; 36 months: 18.6 mg/kg Pts ≥ 36 months: 560 mg/m2) over 60 minutes followed by vincristine sulfate IV (Pts &lt; 36 months: 0.05 mg/kg Pts ≥36 months: 1.5 mg/m2) over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local infrared laser therapy, cryosurgery, and/or radiation therapy (radioactive) plaque comprising iodine I 125 or ruthenium Ru 106.
cryosurgery: Application of extreme cold to destroy abnormal or diseased tissue.
infrared laser therapy: Laser therapy or “photobiomodulation” is the use of specific wavelength of light (red and near-infrared) to create therapeutic effects
iodine I 125: Undergo radioactive therapy
ruthenium Ru 106: Undergo radioactive therapy
carboplatin: Given IV
vincristine sulfate: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Tumor requires non-protocol chemotherapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Tumor requires non-protocol radiotherapy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vincristine Sulfate and Carboplatin and Surgery</title>
          <description>Patients receive chemoreduction comprising carboplatin IV (Pts &lt; 36 months: 18.6 mg/kg Pts ≥ 36 months: 560 mg/m2) over 60 minutes followed by vincristine sulfate IV (Pts &lt; 36 months: 0.05 mg/kg Pts ≥36 months: 1.5 mg/m2) over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local infrared laser therapy, cryosurgery, and/or radiation therapy (radioactive) plaque comprising iodine I 125 or ruthenium Ru 106.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Barbados</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event-free Survival</title>
        <description>Proportion of patients with event free survival at 2 years. An event is defined as the need for non-protocol therapy, defined as additional on-protocol chemotherapy, enucleation or external beam radiation, among patients with Group B intraocular tumors with a schedule of neoadjuvant 2-agent (Vincristine/Carboplatin) chemotherapy (chemo-reduction) and standardized local ophthalmic therapy.</description>
        <time_frame>At 2 years</time_frame>
        <population>One patient was ineligible and was not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vincristine Sulfate and Carboplatin and Surgery</title>
            <description>Patients receive chemoreduction comprising carboplatin IV (Pts &lt; 36 months: 18.6 mg/kg Pts ≥ 36 months: 560 mg/m2) over 60 minutes followed by vincristine sulfate IV (Pts &lt; 36 months: 0.05 mg/kg Pts ≥36 months: 1.5 mg/m2) over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local infrared laser therapy, cryosurgery, and/or radiation therapy (radioactive) plaque comprising iodine I 125 or ruthenium Ru 106.
cryosurgery: Application of extreme cold to destroy abnormal or diseased tissue.
infrared laser therapy: Laser therapy or “photobiomodulation” is the use of specific wavelength of light (red and near-infrared) to create therapeutic effects
iodine I 125: Undergo radioactive therapy
ruthenium Ru 106: Undergo radioactive therapy
carboplatin: Given IV
vincristine sulfate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <description>Proportion of patients with event free survival at 2 years. An event is defined as the need for non-protocol therapy, defined as additional on-protocol chemotherapy, enucleation or external beam radiation, among patients with Group B intraocular tumors with a schedule of neoadjuvant 2-agent (Vincristine/Carboplatin) chemotherapy (chemo-reduction) and standardized local ophthalmic therapy.</description>
          <population>One patient was ineligible and was not included in the analysis.</population>
          <units>Proportion</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".7" lower_limit=".41" upper_limit=".98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Nonprotocol Chemotherapy</title>
        <description>Use of nonprotocol chemotherapy at the patient level and enucleation and EBRT will be descriptively summarized at the patient and eye levels.</description>
        <time_frame>Up to 10 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (RR) at Patient and Eye Levels After the First Course</title>
        <description>RR will be estimated. The response after 1 course of chemotherapy will be used to better define response to this neoadjuvant systemic chemotherapy, prior to the use of local ophthalmic therapy. Response to subsequent courses will help define response to combined systemic chemotherapy and local ophthalmic therapy.</description>
        <time_frame>Up to 10 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival Rate (EFSR) Defined as the Need for Non-protocol Chemotherapy, Enucleation, or EBRT at the Patient Level</title>
        <description>EFSR will be estimated for patients who respond to vincristine and carboplatin after an initial 1 cycle of chemoreduction</description>
        <time_frame>Up to 10 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0</title>
        <time_frame>From the beginning of treatment, assessed up to 10 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events grade 3 and above were considered as Serious Adverse Events in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vincristine Sulfate and Carboplatin and Surgery</title>
          <description>Patients receive chemoreduction comprising carboplatin IV (Pts &lt; 36 months: 18.6 mg/kg Pts ≥ 36 months: 560 mg/m2) over 60 minutes followed by vincristine sulfate IV (Pts &lt; 36 months: 0.05 mg/kg Pts ≥36 months: 1.5 mg/m2) over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local infrared laser therapy, cryosurgery, and/or radiation therapy (radioactive) plaque comprising iodine I 125 or ruthenium Ru 106.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Must obtain prior Sponsor approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>352-273-0567</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

